New drug trial aims to keep aggressive lymphoma at bay
NCT ID NCT07347288
Summary
This study is testing whether a drug called SHR2554 can help prevent cancer from coming back in people with peripheral T-cell lymphoma (PTCL) who have already responded to their first treatment. It will enroll about 30 adults who achieved a partial or complete response after initial therapy. The main goal is to see if taking SHR2554 as a maintenance therapy safely extends the time patients live without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PTCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, 210000, China
Conditions
Explore the condition pages connected to this study.